• / Free eNewsletters & Magazine
  • / My Account
Home>Drug Companies

Drug Companies

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. 5th World Congress of WUWHS: APR Presents the Latest Clinical Outcomes on the Management of Leg Ulcers with Nexodyn®

    5th World Congress of WUWHS: APR Presents the Latest Clinical Outcomes on the Management of Leg Ulcers with Nexodyn®

  2. BIO Applauds Senate Passage of Advancing Hope Act

    BIO Applauds Senate Passage of Advancing Hope Act

  3. Ironwood Closes $150 Million Debt Refinancing

    Ironwood Closes $150 Million Debt Refinancing

  4. Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

  5. Singapore August Industrial Output Nearly Flat

    Singapore August Industrial Output Nearly Flat

  6. Nolato Acquires Swiss Company Treff

    Nolato Acquires Swiss Company Treff

  7. KaleBios says it's current on its financials after 10-Q filing

    KaleBios says it's current on its financials after 10-Q filing

  8. Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets

    Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets

  9. Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic ...

    Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

  10. Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

    Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.